Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin initiation in primary care for type 2 diabetes with CGM versus finger-prick monitoring
ACTRN12610000797077Phase 4Recruiting
- Sponsor
- Sanofi
- Start
- Nov 2010
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine and insulin glulisine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Change in HbA1c from baseline. Started Nov 2010; status: recruiting.
02
Drugs
insulin glargineinsulin glulisine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12610000797077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000797077.